Yonsei University Health System Severance Hospital
Welcome,         Profile    Billing    Logout  
 59 Trials 
76 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Dong Soon
NCT06113198 / 2023-000764-58: A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Recruiting
4
50
RoW
rMenB+OMV NZ
GlaxoSmithKline, GlaxoSmithKline Biologicals SA
Meningitis, Meningococcal
04/26
09/26
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
4
2076
Europe, Canada, US, RoW
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance
Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Motor Function, Cognitive Function, Contrast Media
12/28
12/28
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years

Recruiting
3
249
RoW
DTaP-IPV combination vaccine
Boryung Biopharma Co., Ltd.
Diphtheria, Tetanus, Pertussis, Poliomyelitis
12/20
07/21
NCT05051332: Phase 3 Clinical Trial of CartiLife® in Korea

Active, not recruiting
3
104
RoW
Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery
Biosolution Co., Ltd.
Articular Cartilage Defect, Articular Cartilage Degeneration
09/23
09/24
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT03459534: A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Recruiting
3
173
RoW
Radotinib HCl, SUPECT
Il-Yang Pharm. Co., Ltd.
Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome
06/26
12/27
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
NCT05733624: Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Completed
2
116
RoW
SCAI-001 0.01% eyedrop, Cyclosporine 0.01%, SCAI-001 0.02% eyedrop, Cyclosporine 0.02%, Restasis 0.05% eyedrop, Cyclosporine 0.05%
SCAI Therapeutics
Dry Eye Syndromes
08/23
02/24
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Recruiting
2
50
RoW
EB-203
EyebioKorea, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
08/25
01/26
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
NCT04775706 / 2021-000176-11: Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects

Recruiting
2
18
Europe, US, RoW
HM15912 Active, Placebo
Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd.
Short Bowel Syndrome
12/27
05/28
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Recruiting
1
244
Canada, Japan, US, RoW
GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448
GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics
Neoplasms
09/25
09/25
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Active, not recruiting
1
16
Europe, Japan, US, RoW
Mezagitamab, TAK-079
Takeda
Kidney Disease, Glomerulonephritis
03/26
03/26
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
12/26
12/26
Kim, Ki Hwan
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years

Recruiting
3
249
RoW
DTaP-IPV combination vaccine
Boryung Biopharma Co., Ltd.
Diphtheria, Tetanus, Pertussis, Poliomyelitis
12/20
07/21
NCT04659070: To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

Recruiting
3
156
RoW
Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan
Hanlim Pharm. Co., Ltd.
Primary Hypercholesterolemia, Hypertension
05/22
05/22
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT04903314: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures

Recruiting
1
24
US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
10/25
03/26
Shin, Sang Do
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
4
2076
Europe, Canada, US, RoW
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance
Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Motor Function, Cognitive Function, Contrast Media
12/28
12/28
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
700
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations
06/25
08/26
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting
1/2
110
US, RoW
EU101
Eutilex
Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
09/25
12/25
KEYNOTE-C98, NCT05405595: ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Recruiting
1/2
131
US, RoW
ADG126, Pembrolizumab (KEYTRUDA®)
Adagene Inc, Merck Sharp & Dohme LLC
Advanced/Metastatic Solid Tumors
03/25
09/25
KEYNOTE-B59, NCT04977453: GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Recruiting
1/2
430
US, RoW
GI-101, Pembrolizumab (KEYTRUDA®), KEYTRUDA®, Lenvatinib, Lenvima®, Local Radiotherapy, GI-101A
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Urinary Bladder Cancer, Melanoma, Sarcoma, Microsatellite Stable Colorectal Carcinoma, Merkel Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
10/25
10/26
NCT06421935: M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Recruiting
1
96
Europe, Japan, US, RoW
M9466, HRS-1167;, Tuvusertib, Substance code MSC2584415A; also known as M1774, VXc-400, or VR 1363004, Abiraterone acetate, Abiraterone, Prednisone/Prednisolone
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor
03/26
03/26
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
148
RoW
HM95573, cobimetinib, HM95573, cetuximab
Hanmi Pharmaceutical Company Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor
09/24
12/24
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Active, not recruiting
1
54
Europe, US, RoW
KIN-3248
Kinnate Biopharma
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
06/26
09/26
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
PROVE-DM, NCT05579626: Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus

Recruiting
N/A
4000
RoW
high-intensity statin arm, low-intensity statin plus ezetimibe
Seung-Whan Lee, M.D., Ph.D., Yuhan Corporation
Pre Diabetes, ASCVD
12/27
12/27
Hammers, Hans
NCT04413123: Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Recruiting
2
60
US
Cabozantinib, COMETRIQ™, CABOMETYX™, Nivolumab, Opdivo®, Ipilimumab, Yervoy
Bradley A. McGregor, MD, Bristol-Myers Squibb, Exelixis
Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Renal Cell Carcinoma, Unresectable Advanced Renal Cell Carcinoma, Metastatic Ncc Renal Cell Carcinoma
12/24
12/25
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
NKT2152-202, NCT05935748: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Active, not recruiting
2
172
US
NKT2152, palbociclib, IBRANCE®, sasanlimab
NiKang Therapeutics, Inc., Pfizer
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases
06/25
06/26
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
Kim, Yu Seun
PROUD, NCT05666804: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Recruiting
3
160
RoW
Brolucizumab 6mg, Beovu
Novartis Pharmaceuticals
Macular Polypoidal Choroidal Vasculopathy (PCV)
09/25
09/25
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

Recruiting
2
38
RoW
Avelumab and Gemcitabine
Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp.
Leiomyosarcoma Metastatic
12/21
12/22
KCSG AL19-17, NCT04647838: Tepotinib in Solid Tumors Harboring MET Alterations

Recruiting
2
100
RoW
Tepotinib, MSC2156119J, EMD 1214063
Chungbuk National University Hospital, Merck KGaA, Darmstadt, Germany
Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification
02/23
08/24
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Recruiting
2
40
US, RoW
ABN401
Abion Inc
Advanced Solid Tumors
04/25
08/25
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Recruiting
2
150
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Diabetic Macular Edema (DME)
11/25
12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Recruiting
2
180
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
11/25
12/25
NCT04259450 / 2019-003296-19: Study to Assess AFM24 in Advanced Solid Cancers

Completed
1/2
85
Europe, US, RoW
14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24
Affimed GmbH
Advanced Solid Tumor
07/23
06/24
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
NCT05920135: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Recruiting
1/2
92
US, RoW
BBT-207
Bridge Biotherapeutics, Inc.
EGFR Mutant Advanced Non-Small Cell Lung Cancer
08/26
08/28
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
148
RoW
HM95573, cobimetinib, HM95573, cetuximab
Hanmi Pharmaceutical Company Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor
09/24
12/24
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
Park, Jun Yong
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy

Enrolling by invitation
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
RELIF-C, NCT02865369: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

Not yet recruiting
N/A
103
RoW
Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks
Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb
Chronic Hepatitis C
12/18
12/22
NCT06093321: A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement

Recruiting
N/A
55
RoW
SYB PDO Thread, MINT lift®
Samyang Biopharmaceuticals Corporation
Nasolabial Folds
05/24
02/25
Deleon, Cynthia
NCT05074472: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Completed
1/2
35
US
ZB131
ZielBio, Inc.
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
08/23
09/23
StarBridge-1, NCT05320588: A Study in Patients With Advanced Cancers

Recruiting
1/2
332
US
BIO-106, Pembrolizumab, Keytruda
BiOneCure Therapeutics Inc.
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
04/24
04/27
GLIMMER-01, NCT05259696: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein

Active, not recruiting
1/2
273
US
E-602, Cemiplimab, Libtayo, REGN2810
Palleon Pharmaceuticals, Inc.
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
06/25
06/25
MYCHELANGELO I, NCT05497453: A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

Terminated
1/2
24
US, RoW
OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two, Checkpoint Inhibitor, Immune
Omega Therapeutics
Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Hepatocellular Cancer, Liver Cancer, Liver, Cancer Of, Non-Resectable
11/24
11/24
XTX101-01, NCT04896697: Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Recruiting
1/2
136
US
vilastobart (XTX101), Atezolizumab
Xilio Development, Inc., Hoffmann-La Roche
Advanced Solid Tumor
03/26
03/26
NCT04859777: A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Recruiting
1
70
US
MPT-0118, MPT-0118 + pembrolizumab
Monopteros Therapeutics Inc.
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
03/23
03/23
NCT05698888: Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

Terminated
1
2
US
VP301
Virtuoso BINco, Inc.
Solid Tumors, Adult, Multiple Myeloma, Lymphoma
06/23
06/23
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26
WTX-330x2101, NCT05678998: WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Hourglass Nov 2024 - Nov 2024 : Data from CPI resistant or naive expansion arms for r/r adv tumors
Active, not recruiting
1
75
US
WTX-330
Werewolf Therapeutics, Inc.
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
12/24
02/25
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
ADCT-901-101, NCT04972981: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Active, not recruiting
1
132
Europe, US
ADCT-901
ADC Therapeutics S.A.
Advanced Solid Tumors
04/24
04/25
HBI-2376-101, NCT05163028: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Recruiting
1
42
US
HBI-2376
HUYABIO International, LLC.
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
12/24
12/24
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
KEYNOTE-D17, NCT05479812: Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab (pembro) in Patients with Selected Advanced or Metastatic Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Updated data for adv/m solid tumors
Sep 2023 - Dec 2023: WTX-124 combo pembrolizumab in advanced solid tumors
Recruiting
1
150
US
WTX-124, pembrolizumab, KEYTRUDA®
Werewolf Therapeutics, Inc., Merck Sharp & Dohme LLC
Metastatic Solid Tumor, Advanced Solid Tumor
07/25
07/25
KHALSI-GRAR, Emma
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26

Download Options